drugset / Trial / NCT00429754

Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)

NCT00429754

RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to investigate whether there is an interaction occurs between etoposide and aprepitant in patients with testis carcinoma treated with the standard BEP regimen. Also to determine how long treatment with aprepitant is necessary in BEP regimen for 5 consecutive days.

Timeline

Start
Primary completion
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified

Indications

No indication recorded.